Samsung Settlement Clears Path To Launch US Soliris Biosimilar
Korean Firm And Alexion End Patent Proceedings Over Epysqli Version Of Eculizumab
Samsung Bioepis and Alexion have brought patent proceedings over Soliris to an end in the US, clearing the way for the Korean firm to launch its Epysqli biosimilar version of eculizumab. However, Amgen is also waiting in the wings with its own rival.
